J&J, Legend report Carvykti cut death risk by 45% in multiple myeloma study
Contributor since / Followers
Sundry Photography/iStock Editorial via Getty Images
Johnson & Johnson (NYSE:JNJ) and Legend Biotech (NASDAQ:LEGN) said a long-term study showed their cell therapy Carvykti reduced the risk of death by 45% in certain multiple myeloma patients.
Three-year follow-up data from a Phase 3 study showed patients with relapsed or lenalidomide-refractory multiple myeloma who received a single infusion of Carvykti after at least one prior line of therapy had a 45% lower risk of death compared to standard therapies, according to a statement.
The results were presented at the annual meeting of the International Myeloma Society.
Carvykti was approved by the FDA for the treatment of multiple myeloma in 2022. The therapy was co-developed by J&J (JNJ) and Legend Biotech (LEGN).